Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. logo
HALO

Halozyme Therapeutics, Inc. (HALO)

$56.380.79%

Market is closed
– opens on 8 PM, 07 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$55.64
Day's Range
$56.63
$31.36
52-Week Range
$59.46
1 month return21.82%
3 month return43.06%
1 year return74.28%
5 year return197.21%

Company Information

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.
OrganizationHalozyme Therapeutics, Inc.
Employees145
CEODr. Helen I. Torley M.B. Ch. B., M.R.C.P.
IndustryHealth Technology

Analyst Recommendation

based on 13 analysts ratings

Buy
84%
Buy
7%
Hold
7%
Sell

Based on 13 Wall street analysts offering stock ratings for Halozyme Therapeutics, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Downside of 5.6%

Current

$56.38

Target

$53.22

Recommendation Trend

Based on 13 analyst

Current1M Ago3M Ago
Buy
11
12
11
Hold
1
2
2
Sell
1
1
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
7.6B
Book Value
$0.72
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.54
PE Ratio
36.32
PEG Ratio
-2.5
Wall Street Target Price
53.22

Valuation

Trailing PE36.32
Forward PE23.47
Price/Book (mrq)
82.86
Enterprise Value
9.3B
Enterprise Value/Revenue
15.98
Enterprise Value/Ebitda
31.91

Technicals

Beta
1.25
50 Day MA
47.45
200 Day MA
43.66

Institutional Holdings

BlackRock Inc

13.46%

Vanguard Group Inc

9.86%

State Street Corporation

4.57%

Artisan Partners Limited Partnership

4.53%

Amvescap Plc.

4.12%

William Blair Investment Management, LLC

3.28%

Discover more

Frequently Asked Questions

What is Halozyme Therapeutics, Inc. share price today?

Can Indians buy Halozyme Therapeutics, Inc. shares?

How can I buy Halozyme Therapeutics, Inc. shares from India?

Can Fractional shares of Halozyme Therapeutics, Inc. be purchased?

What are the documents required to start investing in Halozyme Therapeutics, Inc. stocks?

What are today’s High and Low prices of Halozyme Therapeutics, Inc.?

What are today’s traded volumes of Halozyme Therapeutics, Inc.?

What is today’s market capitalisation of Halozyme Therapeutics, Inc.?

What is the 52 Week High and Low Range of Halozyme Therapeutics, Inc.?

How much percentage Halozyme Therapeutics, Inc. is down from its 52 Week High?

How much percentage Halozyme Therapeutics, Inc. is up from its 52 Week low?

What are the historical returns of Halozyme Therapeutics, Inc.?

Who is the Chief Executive Officer (CEO) of Halozyme Therapeutics, Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*